Ligand Pharmaceuticals Incorporated
LGND
주식 순위
#3106
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity,... Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
주가
$291.18
마지막 동기화: 2026-07-31
시가총액
$5.84B
변동 (1일)
-1.73%
변동 (1년)
60.30%
국가
US
거래 Ligand Pharmaceuticals Incorporated (LGND)
카테고리
Healthcare
Ligand Pharmaceuticals Incorporated (LGND)의 영업이익률
October 2026 기준 영업이익률 TTM: 34.74%
Ligand Pharmaceuticals Incorporated의 최신 재무 보고서와 주가에 따르면 현재 영업이익률 (TTM)은 34.74%입니다. 2023년 말 기준 영업이익률은 9.09%였습니다.
Ligand Pharmaceuticals Incorporated의 영업이익률 기록 (2000 ~ 2026)
매년 말 영업이익률
| 연도 | 영업이익률 | 변화 |
|---|---|---|
| 2026 (TTM) | 34.74% | -356.76% |
| 2024 | -13.53% | -248.84% |
| 2023 | 9.09% | 486.45% |
| 2022 | 1.55% | -95.86% |
| 2021 | 37.47% | 63.41% |
| 2020 | 22.93% | -581.72% |
| 2019 | -4.76% | -107.31% |
| 2018 | 65.11% | 34.94% |
| 2017 | 48.25% | 19.82% |
| 2016 | 40.27% | 5.97% |
| 2015 | 38.00% | 24.96% |
| 2014 | 30.41% | -0.33% |
| 2013 | 30.51% | 1,567.21% |
| 2012 | 1.83% | -178.88% |
| 2011 | -2.32% | -98.14% |
| 2010 | -124.50% | 386.33% |
| 2009 | -25.60% | -92.81% |
| 2008 | -356.13% | -23.69% |
| 2007 | -466.69% | 289.79% |
| 2006 | -119.73% | 698.73% |
| 2005 | -14.99% | -34.43% |
| 2004 | -22.86% | 68.21% |
| 2003 | -13.59% | -45.62% |
| 2002 | -24.99% | -17.55% |
| 2001 | -30.31% | -68.22% |
| 2000 | -95.37% | 0.00% |
유사 기업 또는 경쟁사의 영업이익률
| 회사 | 영업이익률 | 영업이익률 차이 | 국가 |
|---|---|---|---|
| 38.59% | -98.89% |
US
|
|
| -149.01% | -104.29% |
US
|
|
| 25.57% | -99.26% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.17% |
NL
|
회사의 영업이익률이란?
영업이익률은 회사의 수익성을 평가하는 핵심 지표입니다. 높은 영업이익률은 일반적으로 긍정적으로 간주되며, 이는 회사가 제품이나 서비스를 생산 비용보다 훨씬 높은 가격에 판매할 수 있음을 보여줍니다. 영업이익률은 회사의 수익을 매출로 나누어 계산합니다.